A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 466 participants.

Also called NCT01582451

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 466 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01582451
Other papers using this trial's data
  • Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5 Diabetes care, 2016-01 DOI, PubMed 26577417

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Czechia, Germany, Greece, Israel, Puerto Rico, Romania, Russia, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01582451. Randomized; no masking; primary purpose treatment. Start 2012-05 (registry gives no type); primary completion 2013-05 (actual). Results posted on 2018-04-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Acronym
IMAGINE 5
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
LY2605541
Intervention (Drug)
Insulin glargine
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01582451
Content hash
13c4e9fcbfaf9471fb4cc5123fdc520a046dc01db85a33f66122ea187c729c3d